Fetal growth in women managed with insulin pump therapy compared to conventional insulin

Kernaghan, D; Farrell, Tom; Hammond, Peter J.; Owen, Philip

doi:10.1016/j.ejogrb.2007.05.006

Cited by 40 publications

(42 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[51][52][53]56 The investigators did not find any studies in pregnant women with T1DM that evaluated maternal mortality, microvascular or macrovascular disease, quality of life, any of the process measures, or birth trauma, and no studies were identified that compared the effectiveness of CSII and MDI in pregnant women with pre-existing T2DM.…”

Section: Methods For Insulin Delivery and Glucose Monitoring In Diabementioning

confidence: 99%

Section: Adults With T1dmmentioning

confidence: 99%

“…[51][52][53][54][55][56] The strength of evidence of the data that compared CSII with MDI among pregnant women with pre-existing T1DM was insufficient for all other maternal and neonatal outcomes due to lack of RCTs and, therefore, a high risk of bias. There was no statistical difference in maternal weight gain, 52,54,56 gestational age at delivery, 51,[53][54][55] birth weight, [53][54][55] and minor congenital anomalies 51,54 between the CSII and MDI intervention groups. Also, meta-analyses of retrospective studies showed nonsignificant relative risks for rates of C-section (RR = 1.01; 95% CI, 0.86-1.20), [53][54][55][56] severe hypoglycemia (RR = 0.78; 95% CI, 0.23-2.65), [54][55][56] admission to the neonatal intensive care unit (RR = 0.84; 95% CI, 0.43-1.68), 54,55 pre-term delivery (RR = 0.98; 95% CI, 0.67-1.43), [53][54][55][56] and frequency of neonatal hypoglycemia (RR = 1.01; 95% CI, 0.86-1.20).…”

Section: Adults With T1dmmentioning

confidence: 99%

“…and fetal outcomes. [51][52][53][54][55][56] The mean age of study participants was 26 to 31 years, with most participants in the CSII group enrolled into the studies prior to becoming pregnant. Most participants had diabetes duration of 7.7 to 13.9 years, with participants in the CSII groups having the longest duration of diabetes.…”

Section: Adults With T1dmmentioning

confidence: 99%

See 3 more Smart Citations

Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review

Golden¹,

Sapir²

2012

JMCP

View full text Add to dashboard Cite

, before training in internal medicine and endocrinology and metabolism at the Johns Hopkins Hospital. During her fellowship in endocrinology, she received a master of health science degree in clinical epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Her primary research interest centers around identifying endocrine risk factors associated with the development of diabetes and cardiovascular disease through the incorporation of measures of hormonal function into the design of clinical trials of cardiovascular risk modification, observational studies of incident cardiovascular disease and diabetes, and studies evaluating diabetic complications. Her current research focuses on studying the neuroendocrine response to chronic psychological stress as a risk factor for diabetes and cardiovascular disease. Dr Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. S15 References Target AudiencesThis CME activity is designed to meet the educational needs of physicians, pharmacists, nurses, and case managers involved in the management and care of patients with diabetes. Learning ObjectivesBased on the findings from the Agency for Healthcare Research and Quality' s (AHRQ) comparative effectiveness review of insulin delivery and glucose-monitoring modalities for diabetes, participants should be able to: 1. Compare the benefits of insulin delivery systems in improving clinical outcomes, glycemic control, hypoglycemia, and quality of life in diabetic patients receiving intensive insulin therapy 2. Evaluate the differential effect of glucose-monitoring approaches on the process measures and intermediate and clinical outcomes in diabetic patients receiving intensive insulin therapy 3. Apply the AHRQ findings to guide effective, patient-centered clinical decisions Funding There is no fee for this CME/CE activity. This learning activity was prepared and funded under contract HHSA290201000006G from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Hea...

show abstract

Section: Methods For Insulin Delivery and Glucose Monitoring In Diabementioning

confidence: 99%

Section: Adults With T1dmmentioning

confidence: 99%

Section: Adults With T1dmmentioning

confidence: 99%

Section: Adults With T1dmmentioning

confidence: 99%

See 2 more Smart Citations

Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review

Golden¹,

Sapir²

2012

JMCP

View full text Add to dashboard Cite

show abstract

“…Hinsichtlich der Neuropathie allerdings fanden sich erst unter einem langen Beobachtungszeitraum von 15 Jahren weniger pathologische Biothesiometriebefunde im intensiv behandelten Arm. Auch in der rezenten 10-Jahre-Langzeitanalyse der UKPDS fand sich hinsichtlich der verbesserten glykämischen Kontrolle ein über den Studienzeitraum hinaus anhaltend günstiger Effekt auf die mikrovaskulären Spätkompli-kationen [26].…”

Section: Optimierung Der Glykämischen Kontrolleunclassified